Treatment for Bile Duct Cancer in the Liver

Cholangio Carcinoma Clinical Trial

Official title: Selective Internal Radiation Therapy With Yttrium-90 Resin Microspheres Followed by Gemcitabine Plus Cisplatin for Intra-hepatic Cholangiocarcinoma: A Phase II Study

Status Completed

Clinical Trial Summary

The current standard treatment of inoperable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) is chemotherapy, which is of limited efficacy. The use of selective internal radiotherapy treatment (SIRT-Y90) is proven efficacious in patients with intra-heptic tumor. Previous experience with SIRT is safe in patients with intrahepatic cholangiocarcinoma. This study aims to study the benefits of sequential administration of SIRT followed by standard chemotherapy for treatment of inoperable intrahepatic cholangiocarcinoma.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cholangio Carcinoma
• Cholangiocarcinoma

• NCT number: NCT02167711
• Study type: Interventional
• Source: Chinese University of Hong Kong
• Status: Completed
• Phase: Phase 2
• Start date: September 17, 2014
• Completion date: February 8, 2023